Status:
ACTIVE_NOT_RECRUITING
Searching for Predictive Biomarkers of Efficacy in Small Cell Lung Cancer Patients Treated With Chemotherapy-immunotherapy Combination Using Imaging Mass Cytometry (HYPE)
Lead Sponsor:
University Hospital, Brest
Conditions:
Small Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this retrospective study is to identify predictive biomarkers of efficacy in tumor samples of small cell lung cancer patients treated with chemotherapy-immunotherapy combination using imag...
Detailed Description
Small cell lung cancer patients treated with first-line atezolizumab plus platinum-etoposide regimen with available formalin fixed paraffin embedded (FFPE) biopsies at baseline will be identified from...
Eligibility Criteria
Inclusion
- Patients with extensive or metastatic small cell lung cancer
- Patients who started a first line treatment with atezolizumab plus carboplatin and etoposide in routine practice before February 2021
- Patients with available tumor sample before treatment start
- No objection from living patients
Exclusion
- Patients who started first line treatment with atezolizumab plus carboplatin and etoposide in routine practice after February 2021
- Patients having received immunotherapy in a clinical trial
- Patients with auto-immune disorder
- Patients under legal protection (guardianship, curatorship)
- Patients refusing to participate to the study
Key Trial Info
Start Date :
June 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06558903
Start Date
June 24 2021
End Date
January 1 2025
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Brest
Brest, France, 29609